CN114761420B - 优化的gip肽类似物 - Google Patents

优化的gip肽类似物

Info

Publication number
CN114761420B
CN114761420B CN202080083881.1A CN202080083881A CN114761420B CN 114761420 B CN114761420 B CN 114761420B CN 202080083881 A CN202080083881 A CN 202080083881A CN 114761420 B CN114761420 B CN 114761420B
Authority
CN
China
Prior art keywords
gip
seq
diacid
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080083881.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114761420A (zh
Inventor
M·M·罗森基尔德
A·H·斯巴尔-乌尔里希
D·里伯
S·J·三尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by Individual filed Critical Individual
Publication of CN114761420A publication Critical patent/CN114761420A/zh
Application granted granted Critical
Publication of CN114761420B publication Critical patent/CN114761420B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080083881.1A 2019-12-03 2020-12-03 优化的gip肽类似物 Active CN114761420B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EPPCT/EP2019/083506 2019-12-03
EP20179259.5 2020-06-10
EP20179259 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Publications (2)

Publication Number Publication Date
CN114761420A CN114761420A (zh) 2022-07-15
CN114761420B true CN114761420B (zh) 2026-04-28

Family

ID=71083547

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080083881.1A Active CN114761420B (zh) 2019-12-03 2020-12-03 优化的gip肽类似物

Country Status (10)

Country Link
US (1) US20250346647A2 (https=)
EP (1) EP4069719A1 (https=)
JP (2) JP7788376B2 (https=)
KR (1) KR20220108064A (https=)
CN (1) CN114761420B (https=)
AU (1) AU2020398675A1 (https=)
CA (1) CA3157387A1 (https=)
IL (1) IL293249A (https=)
MX (1) MX2022006737A (https=)
WO (1) WO2021110845A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221661A1 (en) * 2021-06-10 2022-12-15 Alexander HOVARD SPARRE-ULRICH Treatment of obesity and obesity-related disorders
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
KR20070115947A (ko) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
WO2010016940A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
CN107129538B (zh) * 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
IN2014MN02304A (https=) * 2012-05-03 2015-08-07 Zealand Pharma As
ES2685987T3 (es) * 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
KR102743887B1 (ko) * 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
SG11202105586YA (en) * 2018-12-03 2021-06-29 Antag Therapeutics Aps Modified gip peptide analogues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N-and C-terminal modifications improves obesity and metabolic control in high fat fed mice;V. Pathak等;Molecular and Cellular Endocrinology;20150205(第401期);120-129 *

Also Published As

Publication number Publication date
US20250346647A2 (en) 2025-11-13
MX2022006737A (es) 2022-06-14
EP4069719A1 (en) 2022-10-12
JP2023505441A (ja) 2023-02-09
JP2025172864A (ja) 2025-11-26
IL293249A (en) 2022-07-01
CA3157387A1 (en) 2021-06-10
WO2021110845A1 (en) 2021-06-10
CN114761420A (zh) 2022-07-15
US20230416330A1 (en) 2023-12-28
JP7788376B2 (ja) 2025-12-18
KR20220108064A (ko) 2022-08-02
AU2020398675A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US20250376499A1 (en) Modified gip peptide analogues
CN114761420B (zh) 优化的gip肽类似物
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
CN111491658A (zh) 肠促胰岛素类似物及其用途
KR20210071038A (ko) 단백질 타이로신-타이로신 유사체 및 그의 사용 방법
CN110691788B (zh) 长效gip肽类似物
RU2858286C2 (ru) Оптимизированные пептидные аналоги gip
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
EA048422B1 (ru) Соединения-коагонисты gip/glp1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant